Effects of combined SGLT2 inhibitor and DPP-4 inhibitor therapy on advanced glycation end products

Effects of combined SGLT2 inhibitor and DPP-4 inhibitor therapy on advanced glycation end products - Effects of combined SGLT2 inhibitor and DPP-4 inhibitor therapy on advanced glycation end products

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049408

Enrollment

Registered

2022-11-02

Start date

2020-10-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

The patients with type 2 diabetes are treated with SGLT2 inhibitor (2.5 mg/day luseogliflozin, 5 mg/day dapagliflozin, or 25 mg/day empagliflozin) for 3 months The patients with type 2 diabetes are tr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemoglobin A1c level: 6.5-11.5%

Exclusion criteria

Exclusion criteria: eGFR: less than 45 mL/min/1.73 m2

Design outcomes

Primary

Measure	Time frame
Methylglyoxal-derived hydroimidazolone-1 level in serum	—

Secondary

Measure	Time frame
Body weight, Hemoglobin A1c level, serum lipids, and liver function marker	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

info@tonyo.jp052-789-3946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026